An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels

Rating disease progression of Friedreich’s ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database

(2013) Günther Metz et al.   BRAIN

Effects of low-fat or full-fat fermented and non-fermented dairy foods on selected cardiovascular biomarkers in overweight adults

(2013) Paul J. Nestel et al.   BRITISH JOURNAL OF NUTRITION

Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans

(2013) Charles-Henry Cottart et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Pharmacological Screening Using an FXN-EGFP Cellular Genomic Reporter Assay for the Therapy of Friedreich Ataxia

(2013) Lingli Li et al.   PLoS One

Evidence for a Common Mechanism of SIRT1 Regulation by Allosteric Activators

(2013) B. P. Hubbard et al.   SCIENCE

A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma

(2012) Rakesh Popat et al.   BRITISH JOURNAL OF HAEMATOLOGY

SIRT1 Is Required for AMPK Activation and the Beneficial Effects of Resveratrol on Mitochondrial Function

(2012) Nathan L. Price et al.   Cell Metabolism

FXN methylation predicts expression and clinical outcome in Friedreich ataxia

(2011) Marguerite V. Evans-Galea et al.   ANNALS OF NEUROLOGY

Friedreich's ataxia: Past, present and future

(2011) Daniele Marmolino   BRAIN RESEARCH REVIEWS

Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases--Safety, Pharmacokinetics, and Pharmacodynamics

(2011) L. M. Howells et al.   Cancer Prevention Research

Early Changes in Left Ventricular Long-Axis Function in Friedreich Ataxia: Relation with the FXN Gene Mutation and Cardiac Structural Change

(2011) Philip M. Mottram et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia

(2011) Wolfgang Nachbauer et al.   MOVEMENT DISORDERS

Resveratrol Pretreatment Attenuates Cerebral Ischemic Injury by Upregulating Expression of Transcription Factor Nrf2 and HO-1 in Rats

(2011) Junwei Ren et al.   NEUROCHEMICAL RESEARCH

What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol

(2011) Ole Vang et al.   PLoS One

Mammalian Sirtuins: Biological Insights and Disease Relevance

(2010) Marcia C. Haigis et al.   Annual Review of Pathology-Mechanisms of Disease

Resveratrol Modulates Drug- and Carcinogen-Metabolizing Enzymes in a Healthy Volunteer Study

(2010) H.-H. S. Chow et al.   Cancer Prevention Research

Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis

(2010) V. A. Brown et al.   CANCER RESEARCH

Steady-State Pharmacokinetics and Tolerability of Trans-Resveratrol 2000 mg Twice Daily with Food, Quercetin and Alcohol (Ethanol) in Healthy Human Subjects

(2010) Charles la Porte et al.   CLINICAL PHARMACOKINETICS

Reliability, Stability, and Sensitivity to Change and Impairment in Acoustic Measures of Timing and Frequency

(2010) Adam P. Vogel et al.   JOURNAL OF VOICE

Measuring the rate of progression in Friedreich ataxia: Implications for clinical trial design

(2010) Lisa S. Friedman et al.   MOVEMENT DISORDERS

PGC-1alpha Down-Regulation Affects the Antioxidant Response in Friedreich's Ataxia

(2010) Daniele Marmolino et al.   PLoS One

A high throughput electrochemiluminescence assay for the quantification of frataxin protein levels

(2009) Hannes Steinkellner et al.   ANALYTICA CHIMICA ACTA

Urine 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG), a specific marker of oxidative stress, using direct, isocratic LC–MS/MS: Method evaluation and application in study of biological variation in healthy adults

(2009) Kam-fai Lee et al.   CLINICA CHIMICA ACTA

Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARγ pathway as a therapeutic target in Friedreich’s ataxia

(2009) Giovanni Coppola et al.   HUMAN MOLECULAR GENETICS

Friedreich's ataxia impact scale: A new measure striving to provide the flexibility required by today's studies

(2009) Stefan J. Cano et al.   MOVEMENT DISORDERS

Speech perception ability in individuals with Friedreich ataxia

(2008) Gary Rance et al.   BRAIN

PPAR-γ Agonist Azelaoyl PAF Increases Frataxin Protein and mRNA Expression. New Implications for the Friedreich’s Ataxia Therapy

(2008) Daniele Marmolino et al.   CEREBELLUM

Lateral-flow immunoassay for the frataxin protein in Friedreich’s ataxia patients and carriers

(2008) John H. Willis et al.   MOLECULAR GENETICS AND METABOLISM